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Abstract
Selective serotonin reuptake inhibitor use is associated with increased risk of suicidal ideation in
adolescent humans, yet the neuropharmacological basis of this phenomenon is unknown. Consequently,
we examined the behavioural and neurochemical effects of chronic paroxetine (PRX) treatment in adult
and adolescent rats. Rats received PRX in their drinking water (target dose 10 mg/kg) for 22 d, during
which time they were assessed for depression- and anxiety-like behaviours. Subsequent ex-vivo analyses
examined serum PRX concentrations, striatal neurotransmitter content, and regional serotonin and
dopamine transporter (SERT, DAT) binding density. After 11–12 d treatment, PRX-treated adolescent rats
showed a significant inhibition of social interaction while adults were unaffected. After 19–20 d treatment,
adolescents failed to show an antidepressant-like effect of PRX treatment on the forced swim test (FST),
while PRX-treated adults showed a typical decrease in immobility and increase in swimming.
Two PRX-treated adolescents died unexpectedly after the FST suggesting a compromised response to
physical stress. Despite their greater apparent adverse reaction to the drug, adolescents had significantly
lower plasma PRX than adults at day 22 of treatment. Chronic PRX treatment had similar effects in adults
and adolescents on striatal 5-HT (unchanged relative to controls) and 5-HIAA levels (decreased), while
markers of dopaminergic function (DOPAC, HVA, DA turnover) were increased in adults only. SERT
density was up-regulated in the amygdala in PRX-treated adolescents only while DAT density in the
nucleus accumbens was down-regulated only in PRX-treated adults. These data suggest that the immature
rat brain responds differently to PRX and that this might be of use in modelling the atypical response of
human adolescents to antidepressants. The age-specific PRX-induced changes in dopaminergic markers
and SERT and DAT binding provide clues as to the neural mechanisms underlying adverse PRX effects in
adolescent humans.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) have
long dominated the pharmacological treatment of
adult depressive disorders (Mant et al. 2004). While
initially developed for adults, SSRIs have also become
a first-line treatment for adolescents with depression
(Dean et al. 2006). Depressive disorders occur in
approximately 4–8% of adolescents (Birmaher et al.
1998 ; Kapornai & Vetro, 2008) and are associated with
high rates of self-harm, suicidal ideation and attempts ;
school dropout ; psychosocial, vocational and ac-
ademic impairment ; and persistent depression in
adulthood (Birmaher et al. 1998 ; Kapornai & Vetro,
2008 ; Mann et al. 2006 ; Weissman et al. 1999). Fast and
Address for correspondence : Professor I. S. McGregor, School of
Psychology A18, University of Sydney, Sydney, NSW 2006, Australia.
Tel. :+61 2 9351 3571 Fax :+61 2 9351 8023
Email : iain@psych.usyd.edu.au
International Journal of Neuropsychopharmacology (2011), 14, 491–504. f CINP 2011
doi:10.1017/S146114571100006X
ARTICLE
THEMATIC SECTION
Consequences of
Developmental Exposure
to Drugs, Hormones or
Altered Environment
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/14/4/491/729416 by guest on 19 April 2020
effective treatment of adolescent depression is there-
fore of great importance, yet pharmacological ap-
proaches are often problematic. Many antidepressants
show minimal efficacy in young people (Tsapakis et al.
2008 ; Whittington et al. 2004), and SSRIs have been
associatedwithworsening of depression and increased
risk of suicidal ideation and behaviour in adolescents
(Mann et al. 2006 ; Olfson et al. 2006). A black box
warning appears on all SSRIs in the USA, notifying
prescribers and consumers of this risk (Stone et al.
2009). While these effects occur with many SSRIs
(Bridge et al. 2007 ; Hammad et al. 2006), paroxetine
(PRX) is arguably the worst offender (Robertson &
Allison, 2009).
The reason for these effects in adolescents is un-
known, although several possible causes have been
proposed, including non-adherence to medication and
subsequent withdrawal symptoms; activating side-
effects ; and metabolic factors (Caballero & Nahata,
2005). However, few studies have explored potential
neurobiological causes. The serotonin (5-hydroxy-
tryptamine, 5-HT) and dopamine (DA) systems, in
particular, are implicated in the causality of depres-
sion and suicide, are modified by SSRI treatment, and
undergo dramatic reorganization during adolescence,
suggesting a possible involvement of these systems in
treatment-emergent suicidality.
Depression and suicide have been associated with
underactivity of the 5-HT (Mann et al. 2001 ; Ryding
et al. 2008), noradrenaline (NA) (Brunello et al. 2003)
and DA (Yadid & Friedman, 2008) systems and anti-
depressant drugs are thought to act to restore normal
functionality of these systems (Millan, 2004). SSRIs
selectively bind the serotonin transporter (SERT),
inhibiting 5-HT reuptake and enhancing synaptic
5-HT (Frazer, 1997). However, this acute increase in
5-HT is rapidly attenuated by homeostatic activation
of 5-HT1A autoreceptors, which inhibits 5-HT release
(Hensler, 2003 ; Newman et al. 2004). Thus, the thera-
peutic efficacy of SSRIs is delayed 2–4 wk until down-
regulation of these, and other, serotonergic receptors
occurs (Delago, 2004 ; Yamauchi et al. 2006).
Although SSRIs generally have little affinity for
DA receptors or the DA transporter (DAT) (Frazer,
1997), they have both acute and chronic effects on
dopaminergic function (Dunlop & Nemeroff, 2007).
Specifically, dopaminergic activity appears to be
temporarily attenuated by acute SSRI treatment, which
may contribute to the delay in therapeutic efficacy
(Di Matteo et al. 2008 ; Prisco & Esposito, 1995), and
then enhanced by chronic treatment, contributing to
the relief of DA-related symptoms of depression such
as anhedonia (Di Giovanni et al. 2008).
The aforementioned brain changes associated with
SSRI treatment have largely been determined from the
study of adult animals and human subjects and may
not accurately reflect the impact of these drugs on the
immature brain. Instead, these drug effects may be
modified by interaction with developmental changes
occurring during adolescence. Such developmental
effects may be explored through the use of adolescent
animals. The adolescent period in rats occurs from
approximately post-natal day (PND) 28 until PND 55,
and is broadly analogous to the corresponding ado-
lescent period in humans (Spear, 2007). Stereotypical
adolescent behavioural characteristics in both species
include greater risk-taking, novelty-seeking, and social
interaction (Crews et al. 2007) and elevated suscepti-
bility to stress (McCormick et al. 2010). Similarly, ado-
lescence in both species is a period characterized
by neural maturation and reorganization (Paus, 2005),
increases in neurogenesis and synaptic pruning
(Hodes et al. 2009 ; Paus, 2005) and changes in sero-
tonergic (Spear, 2000) and dopaminergic (Crews et al.
2007) functionality. Compared to adult animals, ado-
lescents have higher synaptic 5-HT and elevated 5-HT
receptor and SERT density (Murrin et al. 2007). Striatal
DA receptors, DAT and DA turnover are also elevated
in early adolescence and decline gradually to adult
levels during maturation (Crews et al. 2007).
In order to explore developmental differences in
antidepressant response, the present study investi-
gated differential changes in anxiety- and depression-
like behaviours during chronic PRX administration
in adult (PND 70) and adolescent (PND 28) rats, and
associated developmental differences in plasma PRX
concentration, SERT and DAT density and striatal
monoamines.
Method
Subjects
The subjects were 32 adolescent (PND 28, 77–118 g)
and 32 adult (PND 70, 313–447 g) experimentally
naive male albino Wistar rats (Animal Resource
Centre, Australia). Rats were housed in age- and
treatment-matched groups (four adults or eight ado-
lescents per cage) with food and water freely available,
except for rats given PRX for whom water was
replaced with PRX solution. The colony room was
maintained at 22 xC on a 12-h reversed light/dark
cycle (lights on 21:00 hours), with all behavioural
testing conducted during the dark phase. All exper-
imentation was approved by the University of Sydney
Animal Ethics Committee in accordance with the
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Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes.
Drugs and experimental design
Ratswere randomly assigned into four groups (n=16) :
Adult/PRX, Adult/Con, Adolescent(Ado)/PRX and
Ado/Con, such that half of each developmental cohort
received PRX solution in place of standard drinking
water. Administration via drinking water has pre-
viously been successfully employed in our laboratory
(Thompson et al. 2004) and was chosen due to the
short half-life of PRX (Owens et al. 2000). Paroxetine
hydrochloride was obtained from Sequoia Research
Biochemicals (UK). A target dose of 10 mg/kg was
selected on the basis of previous literature showing
antidepressant and neurochemical effects of this dose
in adult rats (Carlson et al. 1996; Sillaber et al. 2008),
and to approximate therapeutic plasma concentrations
in humans (DeVane, 1999). Prior to target dose ad-
ministration, a half-dose (5 mg/kg) was administered
for 3 d in accordance with recommendations for the
treatment of children and adolescents with SSRIs
(Fleming, 2007). Taking body weight and fluid intake
into account, PRX was dissolved in water at the
appropriate concentration, adjusted continuously, and
administered for 22 d in light-proof bottles in place
of standard drinking water. During treatment, fluid
intake was recorded daily and body weight every 3 d.
Behavioural tests
A schematic of the experimental procedure is shown
in Table 1. Treatment-emergent suicidality is most
prevalent during the early stages of antidepressant
treatment (Jick et al. 2004), and a possible association
exists between these symptoms and the short-term
anxiogenic effects of SSRIs (Harada et al. 2008). In
order to assess whether the response to PRX differs
between adolescents and adults in these early stages of
treatment rats were exposed to a battery of anxiety
tests [emergence, social interaction (SI), and novelty-
suppressed drinking (NSD) tests] during the second
week of the drug administration period. NSD was
conducted towards the end of this week, when it was
feasible that antidepressant effects may be emerging.
A test of antidepressant efficacy, the forced swim
test (FST), was conducted at the end of the drug ad-
ministration period when adolescent rats were aged
PND 46–47. This timing was chosen to mimic the time-
course of the antidepressant response (Delago, 2004)
and to prevent an impact of swim stress on any sub-
sequent behavioural tests.
Emergence test (day 9)
The emergence test was conducted in a 120r120r
60 cm wooden arena with a black floor, three white
walls and one black wall. A 40r24r17 cm black
wooden hide box, with a hinged red Perspex lid, was
placed centrally against the black wall. Two spotlights
with 150 W PAR-78 globes illuminated the arena to
produce a bright open-field aversive to rats. Rats were
placed inside the hide box at the start of the 5-min
testing period. TrackMate v. 1.0 software (Australia)
was used for automatic scoring of behaviours, in-
cluding: (a) latency to emerge, (b) open-field time, and
Table 1. Summary of experimental procedures
Experiment
day
5 mg/kg 10 mg/kg No drug
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Emergence @
SI @ @
NSD @
Forced swima @ @
Euthanasia 1 @
Washouta @ @ @ @ @
Euthanasia 2a @
SI, Social interaction ; NSD, novelty-suppressed drinking.
Adult (PD 70–91, n=32) and adolescent (PD 28–49, n=32) rats received paroxetine (PRX) solution or normal drinking water for
22 d. All rats were exposed to the emergence test, social interaction test, and novelty-suppressed drinking test. Half of the rats
(n=8/group, randomly selected) were exposed to the forced swim test (cohort 1). The remaining rats (cohort 2) were euthanized
on day 22 in preparation for ex-vivo analyses. Rats from cohort 1 were euthanized on day 27 following a 5-d washout period.
aManipulations experienced only by rats from cohort 1.
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(c) risk assessment (time spent with part, but not all,
of the head/body protruding from the hide box).
The arena was cleaned with 50% ethanol after each
test session. Order of testing was counterbalanced by
treatment group.
Social interaction (SI) test (days 11–12)
The SI test was conducted in a 120r120r60 cm
black wooden arena illuminated by a 40 W red lamp.
Age- and treatment-matched pairs of rats of approxi-
mately equal body weight, but from different home
cages, were placed together in the arena for 10 min.
ODlog software (MacroPod software ; http://www.
macropodsoftware.com) was used for manual scoring
of social behaviours, including: (a) following/chasing:
one rat following the other within a distance of two
body-lengths, (b) anogenital interactions, (c) adjacent
interactions : including play-fighting, climbing over/
under, and adjacent lying, (d) head-to-head inter-
actions, and (e) total SI : time spent in all of the
above categories. The apparatus was cleaned with
50% ethanol between test sessions.
Novelty-suppressed drinking (NSD) (day 13)
A novel paradigm, developed in our laboratory, was
employed for the NSD test, loosely based on that pre-
viously reported (Dulawa & Hen, 2005). The general
paradigm examined consumption of a novel palatable
beverage under anxiogenic conditions of bright light,
white noise and a novel apparatus. This test employed
a lickometer apparatus built in our laboratory
(Hargreaves & McGregor, 2007), consisting of 16 sep-
arate 28r19r18 cm drinking chambers. Two 5-mm
metallic lick tubes, each connected to a 60 ml vertical
syringe reservoir, were extended through the back
wall and allowed for delivery of 0.07¡0.005 ml
aliquots of fluid. Rats licked for diluted (33% v/v)
Schweppes raspberry-flavoured cordial for 20 min
under a fixed-ratio 3 reinforcement schedule. Illumi-
nation was achieved using two Par78 150 W flood-
lights and continuous white noise was generated by a
radio tuned off-station (y90 dB). The number of licks
performed by each rat was recorded by custom soft-
ware written using Labview software (National
Instruments, USA). Other behaviours scored included:
(a) latency to perform 10 licks (this criterion was
chosen to control for very short latencies due to iso-
lated investigative licks early in the session, or acci-
dental activation of the lickometer apparatus by the
rat upon entry to the chamber), and (b) total cordial
consumption.
Forced swim test (days 19–20)
Rats (n=8/group, randomly selected) were exposed
to the modified Porsolt FST as previously described
(Detke & Lucki, 1995). Testing was conducted over
2 d, with a 15-min pretest on day 1 and a 5-min
test 24 h later. Rats were placed in a clear Perspex
cylinder (46 cm high, 22 cm diameter) containing
water (24¡1 xC) to a depth of 30 cm. The room was
illuminated with a 40 W red lamp, and miniature
video cameras relayed images to a video recorder and
computer in an adjacent room. An observer, blind
to group assignment, manually scored behaviours
during the 5-min test session using ODlog software.
Scoring was conducted by dividing the test period into
5-s intervals and recording the dominant behaviour
(swimming, climbing, immobility) during each inter-
val, as recommended for detection of SSRI-induced
behavioural changes (Cryan et al. 2002). Tubes were
cleaned and refilled with fresh water between trials.
After completion of the session, rats were immediately
removed from the chambers, gently towelled and
placed in a cage for drying.
Neurochemical analysis
On day 22 of drug administration, the 32 rats
(n=8/group) that did not experience the FST were
euthanized by decapitation. Brains were removed and
the left and right striatummanually dissected out over
ice, snap-frozen in liquid nitrogen and stored at
x80 xC. Samples were then processed for biogenic
amine content by high-performance liquid chromato-
graphy (HPLC) with electrochemical detection as
described previously (Clemens et al. 2005) with slight
modification.
Biogenic amines were separated using a Phenom-
enex Synergi Polar-RP 80A (250r4.6 mm) reversed-
phase column coupled with a 1-mm Optiguard C18
pre-column maintained at 30 xC. The mobile phase
consisted of 0.1 M phosphate buffer (pH 3.0), 0.74 mM
PICB-8 octane sulfonic acid (Waters, Australia), 0.3 mM
sodium EDTA and methanol (18% v/v). The flow rate
was 0.7 ml/min.
SERT and DAT autoradiography
From day 22 of drug administration the remaining
PRX-treated rats (n=8/group) underwent drug wash-
out with standard drinking water for 5 d. Drug
washout was conducted prior to SERT/DAT auto-
radiography due to possible competition between the
radioligand used and exogenous PRX remaining in
the animal (Hirano et al. 2005). Five days was deemed
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appropriate, with animals being drug free for 15 half-
lives of PRX (Owens et al. 2000).
Subsequently, rats were euthanized by decapi-
tation. Trunk blood was collected and brains removed,
snap-frozen in liquid nitrogen, and stored at x80 xC.
Coronal sections (20 mm) were cut on a Microm
cryostat, and mounted onto polysine-coated slides
(LabServ, Australia). [125I]RTI-55 (Perkin Elmer, USA)
was used to assess binding density for SERT and
DAT as described previously (Kindlundh-Hogberg
et al. 2007). SERT binding was determined at the level
of the hippocampus and central amygdala (Bregma
x2.7 mm), while DAT was assessed within the
striatum (Bregma+1.3 mm).
Slides were apposed for 4 d to Kodak Biomax
MR film in the presence of standard 14C microscales
(American Radiochemical Company, USA). Auto-
radiographs were developed using Kodak developer
and fixer. Films were scanned using a Bio-Rad GS-800
calibrated densitometer and analysed using ImageJ
software (NIH, USA). Standard curves were calculated
for conversion of optical density to nCi/mg radio-
activity concentration, using calibrated microscales.
Serum PRX determination
Trunk blood samples were collected in pre-chilled
lithium-heparin blood tubes immediately following
decapitation. Serum was separated from cells by
centrifugation (3300 g, 4 xC, 15 min) and PRX content
determined using a solid-phase extraction (SPE) col-
umn and HPLCwith ultraviolet detection as described
previously (Li et al. 2004) with slight modification.
An SPE system, consisting of SPEC 3ML MP3
(15 mg) microcolumns (Varian, Australia) connected
to a Vac Elut vacuum manifold, was used for sample
extraction. Five ml of the resulting solution was then
automatically injected into the previously described
HPLC system. PRX and the internal standard, clomi-
pramine, were separated using a Waters Symmetry C8
5-mm (2.1r150 mm) microbore reverse-phase column
coupled with a 1-mm Optiguard C8 pre-column.
A Shimadzu SPD-M10Avp diode array detector
(Kyoto, Japan) monitored at 295 nm was used for
quantification.
Statistical analysis
Data were analysed by between-subjects or mixed-
model ANOVA followed by planned contrasts com-
paring (a) Ado PRX vs. Con, and (b) Adult PRX vs.
Con. Analyses were conducted using SPSS 15 for
Windows (SPSS Inc., USA) with significance levels set
at 0.05.
Results
Behavioural effects
Body weight
Mixed-model ANOVA revealed no overall effects of
PRX on body weight throughout the treatment period
(main effect : p>0.05 ; Fig. 1). As expected, adult
rats weighed more than adolescents [F(1, 60)=1238.01,
p<0.001], and the main effects were modulated
by significant effects of day of drug administration
[daymain effect: F(6, 360)=1684.63, p<0.001; dayrage
interaction: F(6, 360)=371.09, p<0.001; dayrtreatment
interaction: F(6, 360)=4.16, p<0.001 ; dayrager
treatment interaction : F(6, 360)=2.86, p<0.05].
Further comparisons investigating these interactions
revealed no differences in body weight between treat-
ment groups of the same age either before or during
PRX administration, except on day 6 when PRX-
treated adults weighed less than age-matched controls
[F(1, 60)=4.26, p<0.05].
Fluid intake
Overall, PRX-treated rats consumed less fluid than
controls [F(1, 8)=71.94, p<0.001]. Although adults
consumed more than adolescents [F(1, 8)=45.73,
p<0.001], the reduction in intake due to PRX was
greater for adult than adolescent rats [F(1, 8)=14.08,
p<0.01]. Further comparisons revealed that intake
was significantly higher in Adult/Con than Adult/
PRX rats at all time-points following the introduction
of PRX (p<0.05) although no difference in intake was
present prior to PRX administration. In adolescents,
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Fig. 1. Effects of 22 d paroxetine (PRX, 10 mg/kg)
administration on body weight of adult and adolescent (Ado)
rats (n=16/group). Data are presented as average body
weight (g) over treatment (mean¡S.E.M.).
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fluid intake did not differ between treated and un-
treated groups before or during PRX administration,
except on day 21 when PRX reduced intake [F(1, 8)=
6.93, p<0.05]. Averaged over all days, Adult/Con rats
consumed 47.33¡2.42 ml/rat.d, which was signifi-
cantly more than Adult/PRX rats (28.00¡.31 ml/rat.d),
[F(1, 8)=82.66, p<0.001]. In contrast, Ado/Con rats
consumed 27.97¡.44 ml/rat.d, which did not differ
from the 22.46¡0.39 ml consumed by Adolescent/
PRX rats.
Emergence test
Overall, PRX was anxiogenic on the emergence test,
decreasing open-field time [F(1, 60)=8.75, p<0.01 ;
Fig. 2a] and increasing latency to emerge [F(1, 60)=
8.05, p<0.01 ; Fig. 2b]. PRX treatment reduced open-
field time in adolescents [F(1, 60)=4.84, p<0.05] and
increased latency to emerge in adults [F(1, 60)=4.38,
p<0.05]. No differences in risk assessment time were
detected in either age group as a result of PRX
administration.
Social interaction
Overall, PRX-treated rats spent less time in SI than
control rats [F(1, 28)=9.76, p<0.01 ; Fig. 3a]. In ado-
lescents, PRX significantly reduced total SI [F(1, 28)=
20.40, p<0.001 ; Fig. 3a], following [F(1, 28)=7.90,
p<0.01 ; Fig. 3b], adjacent interactions [F(1, 28)=30.34,
p<0.001 ; Fig. 3c] and head-to-head interactions
[F(1, 28)=9.51, p<0.01 ; Fig. 3d]. Conversely, there was
no effect of PRX on adult social behaviours, or on
anogenital interactions in either age group.
Novelty-suppressed drinking
PRX was anxiogenic on the NSD test, increasing
latency to reach criterion (10 licks) [F(1, 60)=4.19,
p<0.05 ; Fig. 4a]. These anxiogenic effects were
somewhat more pronounced in adolescents, who
displayed a greater inhibition of consumption in re-
sponse to PRX than adults [interaction : F(1, 60)=6.15,
p<0.05 ; Fig. 4b]. However, overall, neither age nor
treatment altered overall consumption. There were no
age or interaction effects on latency to criterion.
Forced swim test
Data from one Adult/PRX rat was lost due to com-
puter malfunction. An antidepressant effect of PRX
was apparent in adult rats, with increased swimming
[F(1, 25)=4.39, p<0.05 ; Fig. 5a] and decreased immo-
bility [F(1, 25)=5.04, p<0.05 ; Fig. 5b] in PRX-treated
compared to control adults. PRX had no effect on
climbing in adults. Conversely, there were no differ-
ences between control and PRX-treated adolescents on
swimming, climbing or immobility. In addition, the
FST was associated with two unexpected fatalities
in adolescents treated with PRX, with one rat found
deceased immediately following the pre-test swim,
and the other discovered deceased in the home cage
the following morning.
Neurochemical analysis
Results of neurochemical analysis are presented in
Table 2. Two-way ANOVA revealed a reduction in
5-hydroxyindoleacetic acid (5-HIAA) [F(1, 28)=42.89,
p<0.001] and 5-HT turnover [F(1, 28)=38.93, p<0.001]
in PRX-treated rats of both ages compared to control
rats. There was no overall effect of age on 5-HIAA or
5-HT turnover, or any two-way interaction on either
measure. 5-HT was not affected by either variable.
Analysis of dopaminergic markers revealed lower
DA [F(1, 28)=10.04, p<0.01], higher DA turnover
[F(1, 28)=11.43, p<0.01] and a trend towards lower
dihydroxyphenylacetic acid (DOPAC) [F(1, 28)=4.01,
p=0.055] in adolescent compared to adult rats. There
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Fig. 2. Effects of paroxetine (PRX, 10 mg/kg) on anxiety-like behaviours in the emergence test (5-min duration, conducted on
day 9 of the drug administration period). (a) Time spent in the open field, (b) latency to emerge from the hide box into the
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were no overall effects of treatment on any dopami-
nergic markers. However, PRX had differential effects
in adults and adolescents, as demonstrated by signifi-
cant interaction effects for DOPAC [F(1, 28)=5.10,
p<0.05], homovanillic acid (HVA) [F(1, 28)=8.28,
p<0.01] and DA turnover [F(1, 28)=6.58, p<0.05].
Further analysis revealed higher HVA [F(1, 28)=6.53,
p<0.05] and DA turnover [F(1, 28)=7.75, p=0.01] in
PRX-treated than in control adults, with a numerical
increase in DOPAC [F(1, 28)=2.71, p=0.11]. There
were no such effects in adolescents. Overall, DA did
not vary according to treatment or treatmentrage
interaction.
There were no age, treatment or interaction effects
for NA.
SERT and DAT autoradiography
There were age-specific effects of PRX on SERT den-
sity in the basolateral amygdala (BLA) [interaction :
F(1, 24)=5.22, p<0.05], with SERT density increased
in PRX-treated adolescents [F(1, 24)=5.28, p<0.05],
but not in adult rats (Table 3; Fig. 6). There were no
observable effects of drug or developmental stage on
SERT binding in the CA3 region of the hippocampus.
DAT binding density in the nucleus accumbens (NAc)
core was differentially altered by PRX in adult and
adolescent rats [interaction : F(1, 23)=7.84, p=0.01],
despite the absence of an overall age or treatment
effect. Further comparisons revealed a significant de-
crease in NAc DAT in adults [F(1, 23)=6.24, p<0.05]
but not adolescents. There were no effects on DAT in
the medial and lateral caudate putamen (CPu).
Plasma PRX levels
Analysis of serum samples from PRX-treated rats (no
washout) revealed significantly lower PRX concen-
trations in adolescents (105.19¡17.49 nmol/l) than in
adults (308.59¡80.52 nmol/l), [F(1, 14)=6.09, p<0.05 ;
Fig. 7]. Samples collected following the 5-d washout
showed no detectable PRX.
Discussion
Antidepressant treatment of adolescents with de-
pression is very common (Dean et al. 2006), yet many
studies report minimal efficacy and increased inci-
dence of suicidal ideation in adolescents treated with
SSRIs (Bridge et al. 2007 ; Whittington et al. 2004).
In agreement with these findings, we report that PRX
is associatedwith no antidepressant efficacy and greater
adverse effects in adolescent than in adult rats, despite
lower serum PRX concentrations in adolescents.
We also provide evidence for age-specific changes in
neurochemistry and SERT and DAT binding.
Adult/PRX rats displayed decreased immobility
and increased swimming, indicative of a SSRI-
induced antidepressant response (Bylund & Reed,
2007). However, there was a conspicuous lack of anti-
depressant-like effects of chronic PRX in adolescent
rats in the FST. This agrees with recent reports of
Table 2. Neurochemical analysis of striatal monoamine levels and turnover ratios
Measure
Adult Adolescent
Control Paroxetine Control Paroxetine
NA 734.7 (108.3) 787.1 (48.5) 852.4 (81.6) 763.5 (62.5)
5-HT 355.8 (14.5) 343.0 (23.2) 366.9 (30.8) 369.7 (14.3)
5-HIAA 598.1 (60.5) 370.2 (12.3)*** 613.9 (30.0) 388.1 (9.5)***
5-HT turnover 1.67 (0.13) 1.11 (0.08)*** 1.72 (0.12) 1.05 (0.02)***
DA 8259.3 (455.1) 8359.8 (469.3) 7326.7 (350.9)a 6789.4 (271.8)a
DOPAC 1785.3 (131.7) 2070.9 (130.7)b 1816.8 (143.4) 1548.0 (72.3)b
HVA 765.6 (62.4) 968.1 (80.0)* 947.6 (40.3) 827.8 (25.4)
DA turnover 0.09 (<0.01) 0.12 (0.01)** 0.13 (<0.01) 0.12 (<0.01)
NA, Noradrenaline ; 5-HT, serotonin ; 5-HIAA, 5-hydroxyindoleacetic acid ; 5-HT turnover=5-HIAA/5-HT; DA, dopamine ;
DOPAC, dihydroxyphenylacetic acid ; HVA, homovanillic acid ; DA turnover=HVA/DA.
Monoamine concentrations and turnover ratios were analysed over the left and right striatum following euthanasia on day 22 of
the drug administration period.
Units of measurement are ng/g wet tissue. Data represent mean (¡S.E.M.), n=8/group.
* p<0.05, ** p<0.01, *** p<0.001, paroxetine vs. control group by age.
a Indicates significant overall effect of age (p<0.05).
b Indicates significant age x treatment interaction effect (p<0.05).
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age-specific lack of SSRI efficacy in rodents in the
FST and novelty-suppressed feeding (NSF) paradigms
(Mason et al. 2009 ; Oh et al. 2009). It should, however,
be acknowledged in the present study that adolescents
showed lower overall levels of immobility and high
levels of swimming regardless of drug treatment
and this may have precluded detection of an anti-
depressant response due to a ceiling effect. An anti-
depressant response of adolescents on the FST may
have become apparent with a higher dose of PRX
given to adolescents.
It is also important to acknowledge that although
adolescents and adults received equivalent doses of
PRX, mean plasma levels in adults were almost 3-fold
those seen in adolescents. Therefore differential effects
of PRX in adolescents in the FST might also reflect the
lower systemic PRX levels achieved in adolescents.
The cytochrome P450 enzymes 2D6 and 3A4, which
are largely responsible for SSRI metabolism, are
elevated during childhood and adolescence causing
accelerated hepatic metabolism of the parent drug
(Caballero & Nahata, 2005). As PRX has no active
metabolites (Titier et al. 2003), antidepressant efficacy
is lost as the drug is broken down. However, despite
developmental differences plasma PRX levels in both
adolescent and adult rats were well within the thera-
peutic range for humans (10–600 ng/ml; DeVane,
1999), making it arguable whether the PRX concen-
tration in adolescents was insufficient for therapeutic
efficacy.
As the FST is not sensitive to the clinically observed
2–4 wk delay in antidepressant efficacy (Cryan et al.
2002), we also examined PRX effects on the NSD – a
variant of the popular NSF task – as a measure
of efficacy. In contrast to the FST, NSF mimics the
time-course of the antidepressant response and is
only responsive to chronic antidepressant treatment
(Bechtholt et al. 2006). We found no evidence for
PRX-induced anxiolytic effects in this paradigm on
day 13 of drug treatment, finding greater latency to
drink a palatable cordial solution in PRX-treated rats
of both ages. Despite no age differences in the effect
of PRX on latency, the reduction in consumption ap-
peared subtly greater in adolescent rats, suggesting
that the anxiogenic effect of PRX may be somewhat
more pronounced in adolescents than in adults.
Suppression of consumption is unlikely to be attribu-
table to anorexic effects of the drug, since PRX appears
to be free of such effects (Frazer, 1997 ; Keller et al.
2001) and we saw no evidence of weight loss in ado-
lescent PRX-treated rats in the current study. Rather,
the present results can be argued to be consistent with
clinical observations of increased anxiety in many
humans during the early stages of SSRI treatment
(Goodman et al. 2007) and in various animal models of
anxiety (Dulawa & Hen, 2005 ; Koks et al. 2001) with
anxiolytic effects appearing after 3–4 wk (Bechtholt
et al. 2006; Oh et al. 2009). It is possible that these
anxiogenic effects may resolve more quickly in adults
than in adolescents ; in one study 28 d of fluoxetine
administration was anxiogenic in juvenile mice, but
anxiolytic in adults (Oh et al. 2009).
A more robust demonstration of elevated anxiety in
PRX-treated adolescents was apparent in the profound
Table 3. Regional densities of serotonin transporter (SERT) and dopamine transporter (DAT)
Brain region
Adult Adolescent
Control Paroxetine Control Paroxetine
SERT
Bregmax2.7
CA3 3.612 (0.17) 4.122 (0.30) 3.372 (0.38) 3.687 (0.17)
BLA 5.123 (0.24) 4.778 (0.24) 4.612 (0.33) 5.573 (0.33)*
DAT
Bregma+1.3
NAc core 3.159 (0.10) 2.804 (0.05)* 2.680 (0.15) 2.941 (0.15)
Medial CPu 5.137 (0.10) 5.081 (0.16) 4.732 (0.18) 4.970 (0.25)
Lateral CPu 7.303 (0.22) 7.461 (0.26) 6.728 (0.25) 7.189 (0.24)
CA3, field CA3 of the hippocampus; BLA, basolateral amygdala ; NAc, nucleus accumbens ; CPu, caudate putamen.
SERT and DAT densities were analysed after 22 d paroxetine treatment, followed by a 120-h drug-free washout period.
Transporter density was determined using [125I]RTI-55 quantitative autoradiography.
Units of measurement are [125I]RTI-55 specific binding (nCi/mg). Data represent mean (¡S.E.M.), n=5–8/group.
* p<0.05, paroxetine vs. control group by age.
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SI deficits seen in these rats compared to their un-
treated counterparts. In adolescent male rodents (PND
30–40), play-fighting is the dominant social activity
(Pellis & Pellis, 1997). As the SI test was conducted in
adolescents at PND 38, the reduction in SI in PRX-
treated adolescents probably arose from minimization
of play (evidenced by the reduction in adjacent inter-
actions and following/chasing). This is of particular
concern given the importance of social play in the de-
velopment of normal adult sexual behaviour (de Jong
et al. 2006 ; Thor & Holloway, 1984). Deficits in social
play are key features of childhood depression (Luby,
2009), and have been observed in animal models of
genetic susceptibility to depression such as the Wistar
Kyoto rat (Malkesman & Weller, 2009). However, it
must be acknowledged that baseline social behaviour
was greater in adolescent than in adult rats, perhaps
providing a greater opportunity to observe inhibitory
drug effects. On the other hand, these age-specific
inhibitory effects might be seen to be all the more
remarkable given the manifestly lower PRX serum
levels seen in adolescents compared to adults.
The sudden death of two PRX-treated adolescent
rats following the FST pre-test session suggests that
PRX may produce a compromised response to physi-
cal stress in adolescents. While the precise cause of
death is unclear, the potency of PRX at the muscarinic
acetylcholinergic receptors (Richelson, 1996) may ad-
versely affect cardiac function. Such potential cardiac
effects are underlined by the recently discovered
link between PRX use in pregnancy and cardiac
malformations in infants (Bar-Oz et al. 2007). Future
experiments exploring cardiotoxicity during adoles-
cent PRX administration might usefully explore such
possibilities.
Subtle, yet possibly important, differences were
seen in the neurochemical response to chronic PRX
treatment in adult and adolescent rats. There were no
age-specific effects of PRX on serotonergic markers,
with decreases in 5-HIAA and 5-HT turnover in
both adults and adolescents. These effects are well
documented in the human and animal literature
(Miura et al. 2007 ; Thompson et al. 2004) and are
thought to result from the SSRI-induced inhibition
and/or down-regulation of SERT (Frazer, 1997; Hirano
et al. 2005), which reduces 5-HT reuptake, preventing
intracellular metabolism of 5-HT to 5-HIAA. There
were, however, age-specific effects of PRX on the DA
system, with general dopaminergic up-regulation in
PRX-treated adults and opposite effects in adolescents.
SSRI-induced up-regulation of the DA system has
been previously reported in adult rodents (Carlson
et al. 1996 ; Sekine et al. 2007 ; Tanda et al. 1994) and
probably occurs indirectly via desensitization/down-
regulation of 5-HT2C receptors, which releases the
DA system from inhibition (Di Giovanni et al. 2008;
Adult/PRX Ado/Con Ado/PRXAdult/Con
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Fig. 6. Representative autoradiograms demonstrating [125I]RTI-55 binding to the serotonin transporter (SERT) and dopamine
transporter (DAT). SERT binding density was measured in the CA3 region of the hippocampus and basolateral amygdala
(Bregma –2.7), while DAT binding was measured in the medial and lateral caudate putamen and nucleus accumbens core
(Bregma (+1.3).
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Fig. 7. Paroxetine (PRX) concentrations (nmol/ml) in rat
serum (n=8/group) following 22 d PRX (10 mg/kg)
administration (no washout).
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Prisco & Esposito, 1995). This may be crucial for the
antidepressant response, particularly the relief of
symptoms such as anhedonia (Di Giovanni et al. 2008 ;
Dunlop & Nemeroff, 2007). The anhedonic conse-
quences of the absence, or partial reversal, of this
dopaminergic up-regulation in adolescents may link
to the lack of antidepressant efficacy and reduced
social interaction (Malkesman & Weller, 2009) ob-
served in the present study.
There were also region-specific changes in SERT
and DAT density following PRX administration, with
significant up-regulation of SERT in the BLA in ado-
lescent rats, and a tendency towards down-regulation
in adults. The minimal effect of PRX on SERT density
in adult rats contrasts with the decreases in SERT
often reported following chronic SSRI treatment
(Benmansour et al. 1999 ; Kovaevi et al. 2010), although
these effects are by no means universal (Gobbi et al.
1997 ; Hrdina & Vu, 1993) and may be an artefact
arising from the short washout periods used in these
studies. Competition between the ligand employed for
detection of SERT binding and SSRIs necessitates an
adequate washout to avoid ‘drug on board’ effects.
In addition, there is some evidence to suggest that
the effects of SSRIs on SERT may be short-lived
(Hirano et al. 2005). The up-regulation in adolescent
rats seen in the present study agrees with observations
of SERT up-regulation in the frontal cortex of peri-
adolescent rats given subchronic fluoxetine (Wegerer
et al. 1999). This may contribute to adverse behavioural
effects : increased membrane SERT would probably
increase 5-HT reuptake, reducing synaptic 5-HT and
perhaps thereby causing increased anxiety and de-
creased SI (Gurtman et al. 2002).
There is little consistent evidence on effects of SSRIs
on DAT density, with some studies suggesting up-
regulation of DAT (Kugaya et al. 2003), but not others
(Chen & Lawrence, 2003). Here we report decreased
DAT binding with PRX administration in adult but not
adolescent rats in the NAc, a key region of the brain’s
reward system. The mechanisms underlying these
effects are unknown, although it may be a compen-
satory response to up-regulation of dopaminergic
tone in PRX-treated adults mediated by 5-HT/DA
interactions via 5-HT1A or 5-HT2C receptor subtypes
(Alex & Pehek, 2007). Interestingly, adolescents may
not experience the SSRI-induced down-regulation of
5-HT2C receptors experienced in adults (Carrey et al.
2002), potentially preventing up-regulation of DA tone
and subsequent effects on DAT.
In conclusion, the present study suggests that PRX
is less efficacious and associated with more adverse
effects in adolescent compared to adult rats. These
conclusions are moderated somewhat by the marked
baseline differences in behaviour seen in drug-free
adolescent rats in the SI test and FST, and also by the
more efficient metabolism of PRX seen in adolescents.
Future comparisons of adult and adolescent anti-
depressant responsiveness might also find it difficult
to avoid these constitutive developmental differences
that cloud the interpretation of adolescent drug effects.
Nonetheless, the age-specific alterations in dopami-
nergic tone and SERT and DAT density in response to
PRX give insight into possible causes of the differential
behavioural response to PRX reported in our study.
In particular, this study points to the possibility that
atypical modulation of adolescent dopaminergic and
serotonergic systems by SSRIs may underlie some of
the adverse reactions to these drugs frequently seen in
young persons.
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